Maravai LifeSciences (MRVI) shares drop 15% premarket as it postpones 2024 earnings release, citing year-end financial review.

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Warren Buffett explained why Berkshire Hathaway will always prefer equity investments to cash, why the firm's investments in Japanese conglomerates is likely to increase, and the traditions he expects ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transfo ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

This annual conference is one of the largest and most informative ... similar to Abbvie’s approach with Humira. During a presentation, Teva also described how the company is expanding its biosimilars ...

We think Sandoz and Teva have excelled at identifying their ... doubled the average number of ANDAs that are approved on an annual basis, from fewer than 300 to more than 700.